Veracyte Inc Revenue Growth Rates (VCYT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Veracyte Inc   (NASDAQ: VCYT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

VCYT's Revenue Growth by Quarter and Year

Veracyte Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VCYT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 150.32
1st Quarter March 134.16
FY 284.48

VCYTs Annual Revenue
Veracyte Inc 's Revenue in the fiscal year 2025 $ 489.53 millions
Veracyte Inc 's Revenue in the fiscal year 2024 $ 412.15 millions
Veracyte Inc 's Revenue in the fiscal year 2023 $ 361.05 millions
Veracyte Inc 's Revenue in the fiscal year 2022 $ 296.54 millions
Veracyte Inc 's Revenue in the fiscal year 2021 $ 219.51 millions




VCYT Revenue second quarter 2026 Y/Y Growth Comment
Veracyte Inc reported Revenue improvement of 23.45% year on year in the second quarter 2026, to $ 150.32 millions, this is lower than Veracyte Inc 's recent average Revenue improvement of 38.11%.

Looking into second quarter 2026 results within Medical Laboratories industry 12 other companies have achieved higher Revenue growth. While Veracyte Inc ' s Revenue rise of 23.45% ranks overall at the positon no. 907 in the second quarter 2026.


VCYT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 32.81 % 4.26 % 22.29 %
3rd Quarter September - 15.06 % 19.86 % 19.21 %
2nd Quarter June 23.45 % 16.07 % 16.15 % 23.96 %
1st Quarter March 24.79 % 11.02 % 17.5 % 21.6 %
FY   - 18.78 % 14.15 % -

Financial Statements
Veracyte Inc 's second quarter 2026 Revenue $ 150.32 millions VCYT's Income Statement
Veracyte Inc 's second quarter 2025 Revenue $ 121.77 millions Quarterly VCYT's Income Statement


VCYT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 9.41 % -5.21 % 8.98 %
3rd Quarter September - 2.06 % 2.95 % -0.23 %
2nd Quarter June 12.05 % 13.26 % 8.33 % 9.59 %
1st Quarter March -1.33 % 5.01 % -1.38 % 2.64 %
FY (Year on Year)   - 18.78 % 14.15 % -


Back to VCYT Growth rate Comparisons >> Back to VCYT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #186
Overall #907

Revenue Y/Y Growth Statistics
High Average Low
198.64 % 38.11 % -31.3 %
(Mar 31 2022)   (Dec. 30, 2014)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #186
Overall #907
Revenue Y/Y Growth Statistics
High Average Low
198.64 % 38.11 % -31.3 %
(Mar 31 2022)   (Dec. 30, 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Veracyte Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
68.87 % 9.46 % -33.47 %
(Jun 30 2012)  


VCYT's II. Quarter Q/Q Revenue Comment
Veracyte Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.05%, to $ 150.32 millions, from $134.16 millions in the first quarter.

Within Medical Laboratories industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Veracyte Inc 's Revenue growth quarter on quarter, overall rank is 722.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #7
Healthcare Sector #119
Overall #722
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #7
Healthcare Sector #119
Overall #722
Revenue Q/Q Growth Statistics
High Average Low
68.87 % 9.46 % -33.47 %
(Jun 30 2012)  


VCYT's II. Quarter Q/Q Revenue Comment
Veracyte Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.05%, to $ 150.32 millions, from $134.16 millions in the first quarter.

Within Medical Laboratories industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Veracyte Inc 's Revenue growth quarter on quarter, overall rank is 722.


Veracyte Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 544.74 $ 516.18 $ 489.53 $ 455.94 $ 439.66
Y / Y Revenue Growth (TTM) 23.9 % 22.08 % 18.78 % 11.76 % 12.72 %
Year on Year Revenue Growth Overall Ranking # 1217 # 839 # 539 # 444 # 327
Seqeuential Revenue Change (TTM) 5.53 % 5.44 % 7.37 % 3.7 % 3.99 %
Seq. Revenue Growth (TTM) Overall Ranking # 2255 # 1669 # 1446 # 1578 # 1677


Cumulative Revenue growth Comment
Although Veracyte Inc 's Annual Revenue growth year on year were below company's average 23.91% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 23.9% year on year, from 22.08% in Mar 31 2026.

In the Healthcare sector 223 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 839 to 1217.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 224
Overall # 1217

Revenue TTM Y/Y Growth Statistics
High Average Low
103.63 %
 23.91 %
-53.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 329
S&P 500 # 2255
Cumulative Revenue growth Comment
Although Veracyte Inc 's Annual Revenue growth year on year were below company's average 23.91% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 23.9% year on year, from 22.08% in Mar 31 2026.

In the Healthcare sector 223 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 839 to 1217.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 224
Overall # 1217

Revenue TTM Y/Y Growth Statistics
High Average Low
103.63 %
23.91 %
-53.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 329
S&P 500 # 2255




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VCYT's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions


About Veracyte Inc Revenue Growth Rates (VCYT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Veracyte Inc (CIK 1384101).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001384101-26-000044
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Veracyte Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.